Dataset Information


CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation

ABSTRACT: Neuroendocrine (NE) transformation is a mechanism of resistance to targeted therapy in lung and prostate adenocarcinomas leading to poor prognosis. Upregulation of the cell cycle kinase CDC7 occurred in tumors undergoing NE transformation, after TP53/RB1 co-inactivation, leading to induced sensitivity to the CDC7 inhibitor simurosertib. CDC7 inhibition suppressed NE transdifferentiation and extended response to targeted therapy in in vivo models of NE transformation by inducing the proteasome-mediated degradation of MYC, implicated in stemness and histological transformation. Ectopic overexpression of a degradation-resistant MYC isoform reestablished the NE transformation phenotype observed on targeted therapy, even in the presence of simurosertib. CDC7 inhibition also markedly extended response to standard cytotoxics in lung and prostate small cell carcinoma models. These results nominate CDC7 inhibition as a strategy to constrain lineage plasticity and to effectively treat NE tumors. As simurosertib clinical efficacy trials are ongoing, this concept could be readily translated for patients at risk.

ORGANISM(S): Homo sapiens

PROVIDER: GSE265887 | GEO | 2024/05/12


Similar Datasets

2024-05-01 | GSE252566 | GEO
2024-05-01 | GSE252568 | GEO
2024-05-01 | GSE252567 | GEO
2023-07-12 | GSE237071 | GEO
2023-07-12 | GSE237072 | GEO
2023-12-11 | GSE245745 | GEO
2019-12-03 | GSE114326 | GEO
2023-10-12 | GSE223758 | GEO
2024-05-14 | E-MTAB-13179 | biostudies-arrayexpress
2022-10-28 | GSE215653 | GEO